FDA Sets PDUFA Date for Pembrolizumab

Source: Dermatology Times, August 2021

Merck announced that its phase 3 KEYNOTE-716 (NCT03553836) trial investigating pembrolizumab (Keytruda) has met its primary endpoint of recurrence-free survival (RFS) for the treatment of patients with surgically removed stage II melanomas.1

READ THE ORIGINAL FULL ARTICLE